WEGOVY
SEMAGLUTIDE · 9MG · TABLET · ORAL
Open FDA's page for this record- Approval date
- 20251222
- Product number
- 003
- Exclusivity
- Exclusivity code
- I-935
- Exclusivity expiration date
- 20270308
- Exclusivity code
- NP
- Exclusivity expiration date
- 20281222
- Patents
- Patent number
- 10278923
- Expiration date
- 20340502
- Patent use code
- U-4389
- Patent submission date
- 20260116
- Patent number
- 11033499
- Expiration date
- 20330619
- Drug product flag
- true
- Patent use code
- U-4496
- Patent submission date
- 20260507
- Patent number
- 11382957
- Expiration date
- 20311216
- Drug product flag
- true
- Patent submission date
- 20260116
- Patent number
- 11833248
- Expiration date
- 20390201
- Drug product flag
- true
- Patent use code
- U-4387
- Patent submission date
- 20260116
- Patent number
- 12239739
- Expiration date
- 20340502
- Patent use code
- U-4388
- Patent submission date
- 20260116
- Patent number
- 12396953
- Expiration date
- 20390201
- Drug product flag
- true
- Patent use code
- U-4387
- Patent submission date
- 20260116
- Patent number
- 8129343
- Expiration date
- 20311205
- Drug substance flag
- true
- Drug product flag
- true
- Patent submission date
- 20260204
- Patent number
- 8536122
- Expiration date
- 20260320
- Drug substance flag
- true
- Drug product flag
- true
- Patent submission date
- 20260204
- Patent number
- 9278123
- Expiration date
- 20311216
- Drug product flag
- true
- Patent use code
- U-4389
- Patent submission date
- 20260205
- Products
- Brand name
- WEGOVY
- Application name
- NOVO
- Application type
- N
- Application number
- 218316
- Reference listed drug
- true
- Reference standard
- true
- Marketing status
- HUMAN PRESCRIPTION DRUG
- Application full name
- NOVO NORDISK INC
- Dosage form
- TABLET
- Route
- ORAL
- Active ingredients
- Name
- SEMAGLUTIDE
- Strength
- 9MG
